Viva Biotech Holdings (FRA:VB0) Long-Term Debt: €40.2 Mil (As of Dec. 2025)


FRA:VB0 Viva Biotech Holdings FRA:VB0
43 GF Score
Price €0.14
GF Value €0.08
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Viva Biotech Holdings Long-Term Debt?

Viva Biotech Holdings FRA:VB0 +6.20% 43 Long-Term Debt is €40.2 Mil as of Dec. 2025. GuruFocus rates FRA:VB0 with a GF Score™ of 43/100 and a GF Value™ of €0.08 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Viva Biotech Holdings's Long-Term Debt for the quarter that ended in Dec. 2025 was €40.2 Mil.

Viva Biotech Holdings's quarterly Long-Term Debt declined from Dec. 2024 (€92.6 Mil) to Jun. 2025 (€63.8 Mil) and declined from Jun. 2025 (€63.8 Mil) to Dec. 2025 (€40.2 Mil).

Viva Biotech Holdings's annual Long-Term Debt declined from Dec. 2023 (€118.4 Mil) to Dec. 2024 (€92.6 Mil) and declined from Dec. 2024 (€92.6 Mil) to Dec. 2025 (€40.2 Mil).

Viva Biotech Holdings  (FRA:VB0) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Viva Biotech Holdings Long-Term Debt Related Terms

Viva Biotech Holdings Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Viva Biotech Holdings's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viva Biotech Holdings Long-Term Debt Chart

Viva Biotech Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 331.83 119.29 118.41 92.60 40.16

Viva Biotech Holdings Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 118.41 0.00 92.60 63.76 40.16
FRA:VB0
43GF Score
Viva Biotech Holdings FRA:VB0
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of €40.2 Mil mean?
Viva Biotech Holdings (FRA:VB0) has a Long-Term Debt of €40.2 Mil as of Dec. 2025.
Is Viva Biotech Holdings' Long-Term Debt too high?
Viva Biotech Holdings' current Long-Term Debt is €40.2 Mil. Overall, Viva Biotech Holdings has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Viva Biotech Holdings' Long-Term Debt compare to VRTX and REGN?
Viva Biotech Holdings' Long-Term Debt of €40.2 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Viva Biotech Holdings's current Long-Term Debt is €40.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viva Biotech Holdings stock overvalued right now?
Based on GuruFocus' analysis, Viva Biotech Holdings (FRA:VB0) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.08, compared to a current price of €0.14 — trading 71.3% above its estimated fair value. The current Long-Term Debt is €40.2 Mil. Viva Biotech Holdings' overall GF Score™ is 43/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Viva Biotech Holdings (FRA:VB0), the current Long-Term Debt is €40.2 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Viva Biotech Holdings (FRA:VB0) Overvalued in 2026?

Based on GuruFocus' analysis, Viva Biotech Holdings stock appears to be overvalued. The current stock price of €0.14 is trading 71.3% above its estimated GF Value™ of €0.08. GuruFocus considers Viva Biotech Holdings to be Significantly Overvalued.

Key valuation signals for FRA:VB0:

  • Long-Term Debt: €40.2 Mil
  • GF Value™: €0.08 vs. price of €0.14 (71.3% above fair value)
  • GF Score™: 43/100 with 5 warning signs

No single metric tells the full story. See the FRA:VB0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Viva Biotech Holdings Business Description

Other Exchanges VBIZF:USA01873:Hong Kong
Address 735 Ziping Road, Pudong New District, Zhoupu Town, Shanghai, CHN, 201318
Viva Biotech Holdings is engaged in providing the structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development. The company operates in three reportable segments, Drug Discovery Services providing structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development; Contract Development Manufacture Organisation providing contract development and manufacturing services for small molecule APIs and intermediates and trading of APIs, intermediates and formulations; and commercialisation services; and Viva BioInnovator making strategic investments in biotechnology startup companies.
43GF Score

Get the complete analysis for FRA:VB0

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.14
Price
€0.08
GF Value